Adeno-associated virus capsid protein mutants

A recombinant AAV1 capsid mutant with enhanced pulmonary vascular tropism addresses the challenge of inefficient gene delivery in pulmonary arterial hypertension, enabling effective gene therapy for targeted treatment and prevention.

JP2024541000AActive Publication Date: 2024-11-06GLUGENETHERAPEUTICS INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024524454
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-23
Filing Date
2022-11-18
Publication Date
2024-11-06
Estimated Expiration
2042-11-18

AI Technical Summary

Technical Problem

Current gene transfer technologies for pulmonary arterial hypertension lack specificity and efficiency in targeting pulmonary blood vessels, leading to delayed diagnosis and poor prognosis.

Method used

Development of a recombinant AAV1 capsid mutant with specific pulmonary vascular tropism, enhanced gene delivery efficiency, and improved transduction profile for targeted gene expression in pulmonary vascular cells.

Benefits of technology

The recombinant AAV1 capsid mutant achieves highly efficient gene delivery and expression in pulmonary vascular cells, potentially preventing or treating pulmonary hypertension by improving diagnostic accuracy and treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541000000001_ABST
    Figure 2024541000000001_ABST
Patent Text Reader

Abstract

The present invention provides a mutant of adeno-associated virus serotype 1 (AAV1) capsid protein, the mutant being an AAV1 capsid protein mutant in which serine at position 430 is replaced with cysteine ​​and isoleucine at position 647 is replaced with valine compared to the amino acid sequence of the wild-type AAV capsid protein, a nucleic acid encoding the mutant AAV1 capsid protein, a recombinant AAV1 vector comprising the nucleic acid encoding the mutant AAV1 capsid protein, and a pharmaceutical composition comprising the vector. In particular, a recombinant viral vector comprising a nucleic acid encoding a mutant AAV1 capsid protein is useful for preventing or treating pulmonary arterial hypertension by improving expression of a transgene in pulmonary vascular target cells when delivered in an aerosol state through the bronchi.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to mutants of adeno-associated virus (AAV) capsid proteins, and in particular recombinant viral vectors containing mutants of the AAV1 capsid protein are useful for expressing transgenes in pulmonary vascular target cells upon aerosol delivery through the bronchi. [Background technology]

[0002] To effectively carry out gene therapy, it is of utmost importance to develop a gene transfer technique that allows the therapeutic gene to be delivered to the desired target cells and to obtain a high expression efficiency.

[0003] Among these gene transfer technologies, AAV is a non-pathogenic virus that has no side effects on the infected cells and has a low probability of causing mutations in the genetic information of target cells, making it safer than other gene therapy technologies.

[0004] AAV (Adeno-Associated Virus) is a non-enveloped single-stranded DNA virus that can infect both dividing and non-dividing cells. AAV can replicate only in the presence of a helper virus and is non-pathogenic to humans. These characteristics make AAV a useful method for introducing genes into various cells and it is used as a useful vector for gene therapy.

[0005] AAV has various serotypes, and it is known that the host and viral characteristics differ depending on the serotype. Serotype 2 (AAV2) is a serotype that has been widely studied for a long time and can infect various cells. Serotype 1 (AAV1), serotype 5 (AAV5), and serotype 6 (AAV6) are serotypes with higher tissue infection specificity, and AAV1 is known to have high gene transfer efficiency in muscles, liver, airways, and central nervous system, AAV5 in the central nervous system, liver, retina, and AAV6 in the heart, muscles, and liver. Although the gene transfer characteristics to specific tissues differ depending on the serotype, it is still easy to transfer to other tissues, so it can be said that the development of new AAV vectors that can improve tissue specificity and improve safety and efficiency is essential.

[0006] On the other hand, pulmonary arterial hypertension is a disease in which the pulmonary arterioles narrow for no particular reason, causing increased pressure in the pulmonary arteries and reduced right ventricular function. Because the main symptoms are common everyday symptoms such as shortness of breath and dizziness, it is often overlooked or mistaken for other diseases. For this reason, it often takes a long time for patients to receive a diagnosis.

[0007] In fact, according to a survey by the Centers for Disease Control and Prevention, it took an average of 1.5 years to accurately diagnose pulmonary arterial hypertension, which required cardiac catheterization, which is expensive and requires inserting wires into the body.

[0008] When blood does not flow smoothly from the heart to the lungs, it can lead to breathing difficulties, heart failure, and in severe cases, death. Despite continuous developments in medical technology, the five-year survival rate for pulmonary arterial hypertension is only about half. As the prognosis is very poor, appropriate early diagnosis and treatment are important.

[0009] Attempts have been made to improve gene transfer efficiency by modifying the AAV capsid protein, but no studies have been reported yet on adeno-associated virus targeting the pulmonary vasculature. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] International Publication No. 2017-201121 (November 23, 2017) [Patent Document 2] Japanese Patent Publication No. 2021-0010372 (February 4, 2021) Summary of the Invention [Problem to be solved by the invention]

[0011] Therefore, the present inventors have made intensive efforts to solve the above problems, and have completed the present invention by developing a protein mutant based on the capsid of a new adeno-associated virus (AAV) serotype 1 that targets the pulmonary blood vessels and has the potential to deliver a gene therapy agent that solves the underlying genetic cause of pulmonary arterial hypertension. [Means for solving the problem]

[0012] Therefore, an object of the present invention is to provide a mutant of AAV1 capsid protein for improving the efficiency of gene transfer into target cells and / or improving the efficiency of genetic information expression by recombinant AAV.

[0013] Another object of the present invention is to provide a nucleic acid encoding a mutant of the AAV1 capsid protein.

[0014] Another object of the present invention is to provide a recombinant AAV1 vector comprising a nucleic acid encoding a mutant of the AAV1 capsid protein.

[0015] Yet another object of the present invention is to provide a pharmaceutical composition comprising the recombinant AAV1 vector.

[0016] It is still another object of the present invention to provide a method for preventing or treating pulmonary hypertension, comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject. Effect of the Invention

[0017] The present invention relates to a recombinant AAV1 capsid mutant capable of specifically targeting the pulmonary vasculature and highly efficient gene transfer. A recombinant viral vector comprising a nucleic acid encoding a mutant AAV1 capsid protein is useful for expressing an introduced gene in pulmonary vascular target cells when delivered in an aerosol state through the bronchi, and is capable of preventing or treating pulmonary vascular diseases. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 shows the 3D structure of the recombinant AAV1 vector (#2-3 mutant). [Figure 2a] FIG. 2a shows the cleavage map of the #2-3 mutant. [Figure 2b] FIG. 2b shows the pHelper plasmid cleavage map. [Figure 2c] FIG. 2c shows the pCMV GFP plasmid cleavage map. [Figure 2d] FIG. 2d shows the pCMV LacZ plasmid cleavage map. [Diagram 3] FIG. 3 shows the entire base sequence of the recombinant AAV1 vector (#2-3 mutant) represented by SEQ ID NO:5 according to the present invention. [Figure 4] FIG. 4 shows the complete nucleotide sequence of the wild-type AAV1 vector. [Diagram 5] FIG. 5 shows a comparison of the packaging efficiency and genomic titer of wild-type AAV1 and the recombinant AAV1 vector of the present invention (#2-3 mutant) through quantitative PCR analysis. [Figure 6]FIG. 6 shows the improvement of transduction efficiency of human pulmonary artery smooth muscle cells (HPASMCs) analyzed by the percentage of cells expressing GFP among all cultured cells. [Figure 7] Figure 7 shows the results of efficient local transduction in lung tissue by confirming the vascular specificity of the recombinant AAV1 vector (#2-3 mutant) in lung tissue, in which whole-mount β-galactosidase staining was performed on lungs excised from 8-week-old C57BL / 6 male mice to confirm LacZ expression. [Figure 8] FIG. 8 quantifies pulmonary vascular smooth muscle cell targeting of recombinant AAV1 vectors (#2-3 mutants). [Figure 9] FIG. 9 shows the Brownian motion of the recombinant AAV1 vector (#2-3 mutant) in 1x PBS (pH 7.4). [Figure 10] FIG. 10 shows the results of confirming targeting and distribution to vascular smooth muscle cells after intratracheal injection of the recombinant AAV1 vector (#2-3 mutant). [Figure 11] FIG. 11 shows the LacZ expression of recombinant AAV1 vector (#2-3 mutant) in blood vessels with a diameter of 100 μm or more, confirmed by x-gal staining [V: vessel, B: bronchus]. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The present invention will be described in more detail below as follows.

[0020] The present invention relates to mutants of the adeno-associated virus serotype 1 (AAV1) capsid protein.

[0021] The term "adeno-associated virus" or "AAV" as used herein refers to all adeno-associated viruses used in gene therapy, including their derivatives, viral subtypes, naturally occurring and recombinant forms. Various serotypes of AAV may be used as recombinant gene transfer viruses to transduce a number of different cell types. The genomic sequences of various serotypes of AAV, as well as the sequences of the natural terminal repeats (TRs), Rep proteins and capsid subunits, are known in the art. Such sequences can be found in the literature or in public databases such as GenBank. For example, see GenBank Accession Nos. NC_002077 (AAV-1), AF063497 (AAV-1).

[0022] As used herein, the term "serotype" refers to a subdivision of AAV that can be identified by serological or DNA sequence analysis and distinguished by its antigenic characteristics.

[0023] The term "capsid" as used herein means a protein encoded by the cap gene present in the genome of a virus, which constitutes the outer coat of the virus. The wild-type AAV genome or cap gene encodes three types of capsid proteins (VP1, VP2, and VP3). In the present specification, all of these are included in the capsid protein. The wild-type AAV1 capsid protein comprises the amino acid sequence represented by SEQ ID NO:1.

[0024] In one embodiment, the present invention provides a mutant of an adeno-associated virus serotype 1 (AAV1) capsid protein, the mutant comprising an AAV1 capsid protein in which serine at position 430 is replaced with cysteine ​​and isoleucine at position 647 is replaced with valine compared to the amino acid sequence of a wild-type AAV1 capsid protein.

[0025] In one embodiment, the mutant AAV1 capsid protein according to the present invention comprises or consists of the amino acid sequence (VP1) set forth in SEQ ID NO: 3. VP2 corresponds to the amino acid sequence from T138 to the end of SEQ ID NO: 3, and VP3 corresponds to the amino acid sequence from M203 to the end of SEQ ID NO: 3.

[0026] In the examples of this application, the mutant AAV1 capsid protein according to the present invention was designated #2-3.

[0027] The term "wild type" as used herein means the type that is most commonly found in wild populations of a species. With respect to mutant types, wild type refers to a phenotype that is considered to be basic or an individual thereof. Wild type is also known as "normal type." In addition, in this specification, "mutant" refers to a protein, virus, cell, individual, etc. in which a mutated gene is manifested as a phenotypic change. In addition, in this specification, "mutant" may refer to the mutated gene itself.

[0028] In one embodiment, the present invention includes a nucleic acid encoding a mutant of the AAV1 capsid protein. The nucleic acid of the present invention encodes a mutant of the AAV1 capsid protein. The nucleic acid of the present invention is prepared by substituting at least one base with another base in the base sequence of the nucleic acid (cap gene) encoding the AAV1 capsid protein. The nucleic acid of the present invention may be in the form of DNA, but may also be in the form of RNA in some cases, or may be a chimera of DNA and RNA. The nucleic acid of the present invention also includes a complementary nucleic acid (e.g., cDNA). The nucleic acid of the present invention may be single-stranded or double-stranded, but is preferably double-stranded.

[0029] The present invention is not particularly limited as a nucleic acid encoding a mutant of AAV1 capsid protein, but in one embodiment, the nucleic acid may have a base sequence represented by SEQ ID NO:4.

[0030] The nucleic acid of the present invention may be operably linked to a suitable control sequence. The control sequence includes a promoter sequence, a polyadenylation signal, a transcription termination sequence, an upstream regulatory domain, an internal ribosome entry site (IRES), an enhancer, and the like. The promoter sequence includes an inducible promoter sequence and a constitutive promoter sequence. The control sequence may be native to the AAV from which the capsid protein is derived, may be foreign, may be a natural sequence, or may be a synthetic sequence. The present invention also includes recombinant DNA capable of expressing a mutant of AAV1 capsid protein comprising the nucleic acid of the present invention.

[0031] The recombinant DNA is useful for delivering the nucleic acid of the invention to cells in vitro, ex vivo and in vivo, and for conferring to the cells the ability to express mutants of AAV1 capsid proteins. The cells delivered with the nucleic acid of the invention are also useful for producing recombinant AAV particles. The recombinant DNA may be used to deliver or introduce the nucleic acid of the invention to eukaryotic cells, preferably animal cells, more preferably mammalian cells, in particular.

[0032] In the present invention, recombinant DNA may be prepared by carrying the nucleic acid of the present invention in a DNA used as a vector, for example, a plasmid, a phage, a transposon, a cosmid, an episomal DNA, a virus genome, etc.

[0033] For example, a packaging plasmid may be generated by carrying a nucleic acid (cap gene) encoding a mutant of the AAV1 capsid protein of the present invention in a plasmid. The packaging plasmid may further include any nucleic acid sequence, such as a nucleic acid (rep gene) encoding a replicase (Rep) protein. Preferably, the rep gene may be supplemented with Rep from AAV2.

[0034] A recombinant DNA containing the nucleic acid of the present invention can also be prepared by replacing at least one base in the PLA2 domain coding region with another base in the nucleic acid sequence of the cap gene carried by a known packaging plasmid. The packaging plasmid is not particularly limited, but includes a packaging plasmid carrying the cap gene, preferably a packaging plasmid carrying the cap gene and the rep gene. As an example, in the present invention, a recombinant AAV1 vector p#2-3 represented by SEQ ID NO: 5, which is a packaging plasmid carrying the nucleic acid (cap gene) encoding the mutant of the AAV1 capsid protein of the present invention and the rep gene, was prepared.

[0035] The method for introducing base substitutions into a nucleic acid can be carried out by known methods and is not particularly limited, but can be achieved by using commercially available reagents, for example, Mutagenesis Basal Kit (TAKARA BIO INC.), and performing PCR according to the instructions included with the kit.

[0036] Thus, the present invention includes novel AAV1#2-3 mutants for gene therapy applications, which are recombinant AAV1 vectors comprising nucleic acids encoding AAV1 capsid protein mutants.

[0037] The recombinant AAV vector of the present invention is useful for gene transfer into target cells. The gene transferred by the recombinant AAV vector of the present invention is strongly expressed in the target cells.

[0038] As used herein, the term "AAV vector" refers to any vector that contains or is derived from components of an adeno-associated virus (AAV) and is suitable for infecting, whether in vitro or in vivo, mammalian cells, including human cells of any of a number of tissue types, such as the brain, heart, lung, skeletal muscle, liver, kidney, spleen or pancreas. The term "AAV vector" may also be used to refer to an AAV-type viral particle (or virion) that contains at least a nucleic acid molecule encoding a protein of interest.

[0039] The term "AAV virus" or "AAV virus particle" or "rAAV vector particle" as used herein refers to a virus particle consisting of at least one AAV capsid protein (by all capsid proteins of wild-type AAV) and a polynucleotide rAAV vector encapsidated within the capsid. When the particle contains a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, e.g., a transgene to be transferred to a mammalian cell), it is typically referred to as a "rAAV vector particle" or simply "rAAV vector". Thus, the production of rAAV particles necessarily includes the production of rAAV, since such vector is contained within the rAAV particle.

[0040] "Packaging" refers to a series of intracellular events that result in assembly of AAV particles and their import into the capsid.

[0041] AAV "rep" and "cap" genes refer to polynucleotide sequences that encode the adeno-associated virus replication and import proteins within the capsid. AAV rep and cap are referred to herein as AAV "packaging genes."

[0042] A "helper virus" for AAV refers to a virus that allows AAV (e.g., wild-type AAV) to be replicated and packaged by mammalian cells. A variety of such helper viruses for AAV are known in the art, including adenoviruses, rupesviruses, and foxviruses such as vaccinia. Adenoviruses include many different subgroups, although type 5 adenoviruses of subgroup C are most commonly used. Numerous adenoviruses of human, non-human mammalian, and avian origin are known and available from depositories such as the ATCC. Herpes family viruses include, for example, herpes simplex viruses (HSV) and Epstein-Barr viruses (EBV), as well as cytomegaloviruses (CMV) and pseudorabies viruses (PRV), which are also available from depositories such as the ATCC.

[0043] "Helper virus function(s)" refers to function(s) encoded in the helper virus genome that permit AAV replication and packaging (along with other requirements for replication and packaging as described herein). As described herein, "helper virus functions" may be provided in a variety of ways, including by providing a helper virus or, for example, by providing a polynucleotide sequence encoding the essential function(s) to a producer cell in trans. For example, a plasmid or other expression vector containing a nucleotide sequence encoding at least one adenovirus protein is transfected into a producer cell along with a rAAV vector.

[0044] In one embodiment, the AAV1 vector according to the present invention has an improved transduction profile for a target tissue compared to an AAV1 vector comprising a wild-type capsid protein, i.e., the AAV1 vector according to the present invention has a distinct tissue targeting ability (e.g., tissue tropism).

[0045] As used herein, the term "tropism" refers to the specificity of AAV capsid proteins present in AAV viral particles to infect or transduce specific types of cells or tissues.

[0046] The tropism of an AAV capsid for a particular cell or tissue type may be determined by measuring the ability of AAV vector particles that contain the AAV1 capsid protein to infect or transduce a particular cell or tissue type using standard assays well known in the art, such as those disclosed in the Examples herein.

[0047] That is, "tropism" refers to the ability of an AAV vector or virion to infect at least one particular cell type, but can also include whether the vector functions to transduce cells of at least one particular cell type, i.e., tropism refers to the preferential introduction of the AAV vector or virion into a particular cell or tissue type(s) and / or preferential interaction with a cell surface that facilitates entry into a particular cell or tissue type, optionally and preferably followed by expression (e.g., transcription and optionally translation) of sequences carried by the AAV vector or virion within the cell, e.g., in the case of a recombinant virus, expression of a heterologous nucleotide sequence(s).

[0048] As used herein, the term "transduction" refers to the ability of an AAV vector or virion to infect at least one particular cell type, i.e., transduction refers to introducing an AAV vector or virion into a cell and transferring the genetic material contained within the AAV vector or virion to the cell to obtain expression from the vector genome. In some, but not all, cases, transduction and tropism are correlated.

[0049] The AAVs described herein contain amino acid modifications in at least one capsid protein that confer new or enhanced tissue tropism properties. The AAV1 modifications according to the present invention target the pulmonary vasculature (e.g., the pulmonary artery).

[0050] As used herein, the term "tropism for lung tissue or pulmonary blood vessels" means tropism for lung tissue or pulmonary blood vessels.

[0051] In one embodiment, the pulmonary vascular tropism of the peptide-modified hybrid AAV capsid protein is increased by at least 5%, 10%, 20%, 30%, 40%, 50% or more compared to the pulmonary vascular tropism of a wild-type AAV capsid protein lacking the peptide.

[0052] The present invention also includes a pharmaceutical composition comprising the recombinant AAV1 vector, which may further comprise a pharma- ceutical acceptable carrier.

[0053] The term "pharmaceutical acceptable carrier" includes any substance that, when combined with an active ingredient of a composition, allows the ingredient to have biological activity without eliciting an undesirable physiological response, such as an unintended immune response. Pharmaceutically acceptable carriers include water, phosphate buffered saline, emulsions such as oil / water emulsions, and wetting agents. Compositions containing such carriers may be formulated by well-known conventional methods, as described in Remington's Pharmaceutical Sciences, current Ed., Mack Publishing Co., Easton Pa. 18042, USA; A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H. C. Ansel et al., 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H. Kibbe et al., 3rd ed. Amer. Pharmaceutical Assoc.

[0054] In one embodiment, the pharmaceutical composition according to the present invention may be a pharmaceutical composition for preventing or treating pulmonary arterial hypertension.

[0055] As used herein, the term "treatment" refers to any type of intervention or process performed on a subject, or the administration of an active agent to a subject, for the purpose of attempting to reverse, alleviate, ameliorate, inhibit, slow or prevent the progression, development, severity or recurrence of disease-related syndromes, complications, symptoms or biochemical signs. Treatment may be performed on diseased or disease-free subjects (e.g., prophylactically).

[0056] In one embodiment, the present invention includes a method for preventing or treating pulmonary arterial hypertension, comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject.

[0057] As used herein, "administration" refers to the physical introduction of a therapeutic agent or a composition containing a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art. Preferred routes of administration include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal, intravitreal, or other parenteral routes of administration, for example, by injection or infusion. As used herein, the term "parenteral administration" generally refers to modes of administration other than enteral and topical administration by injection, including, but not limited to, intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcuticular, intravitreal, intraarticular, subthecal, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion, as well as in vivo electroporation.

[0058] As used herein, the term "therapeutically effective amount" refers to an amount of a drug alone or in combination with other therapeutic agents that is effective to "treat" a disease or disorder in a subject or to reduce the risk, latency, likelihood or occurrence of a disease or disorder (e.g., pulmonary arterial hypertension). A "therapeutically effective amount" includes an amount of a drug or therapeutic agent that provides some improvement or benefit to a subject having or at risk of having a disease or disorder (e.g., pulmonary arterial hypertension as disclosed herein). Hereby, a "therapeutically effective amount" is an amount that reduces the risk, latency, likelihood or occurrence of a disease or disorder, or provides some relief, remission, and / or reduces at least one indicator (e.g., pulmonary arterial hypertension) and / or reduces at least one clinical symptom of a disease or disorder.

[0059] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, and the like. EXAMPLES

[0060] The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to the following examples.

[0061] [Example]

[0062] Example 1: Selection of pulmonary vascular tropic AAV1 capsid protein mutants using an AAV library

[0063] 1) Selection of AAV1 capsid protein mutants Plasmid pools were prepared by random point mutagenesis using error-prone PCR in the cap genes of wild-type AAV mutants (AAV1, AAV2, AAV4, AAV6, AAV8, and AAV9) and insertion of random 7mer / 9mer fragments into 3-fold protrusion of each serotype. 7-70ng of the AAV plasmid library, 25μg of pBluescript, and 25μg of pHelper were combined to form calcium-phosphate complexes, which were then transfected into AAV293 cells for AAV packaging to prepare AAV library pools carrying the cap gene information of each mutant.

[0064] Eight-week-old C57BL / 6 male mice were anesthetized with isoflurane, and the skin around the airway was incised about 1 cm. 1 × 10 of PBS was added to a PenWu micro-aerosolizer (BioJane, Shanghai, China) (1.25" length of intratracheal portion, 700 μm of outer diameter, 430 μm of inner diameter). 11 The AAV library pool was loaded at vg / 100 μl, and the needle was confirmed to pass through the airway, followed by intratracheal injection.

[0065] One week later, the lungs were excised after perfusion with 0.9% saline through the heart. After homogenization, DNA was extracted from the whole lung using a DNA mini kit (Qiagen). The cap gene of an AAV mutant showing tropism in the whole lung was amplified using the AAV cap gene-specific forward primer 5'-GCGGAAGCTTCGATCAACTACG-3' (SEQ ID NO: 7) and reverse primer 5'-CGCAGAGACCAAAGTTCAACTGA-3' (SEQ ID NO: 8). This was prepared from a lung-tropic AAV library pool, and intratracheal injection was performed as described above (1 × 10 11vg / 100μl). After one week, perfusion and lung removal were performed, and the lungs were chopped for 30 seconds to make small pieces, and then single cell dissociation was performed using collagenase II. DNase I was added to prevent cell clustering due to chromosomal DNA released from dead cells and minimize cell loss. After incubation at 37℃ for 4-6 hours, total lung population in the form of single cells was obtained through pipetting, and red blood cell lysis was performed at room temperature in the dark, and the cells were filtered through a cell strainer with 70μm pores and transferred to FACS buffer. Then, 10μg of APC (Anti-alpha smooth muscle actin antibody) was added to select AAV mutants showing vascular tropism, and incubation was performed at 4℃. APC positive cells were then sorted to select vascular-related cells, and after cell lysis and DNA extraction, the cap gene of the AAV mutant that had been introduced into the cells was amplified using primers (5'-GCGGAAGCTTCGATCAACTACG-3': sequence number 9) and (5'-CGCAGAGACCAAAGTTCAACTGA-3': sequence number 10).The amplified cap gene contains HindIII and NotI sequences at both ends, and was subcloned into pSub2 plasmid through HindIII / NotI restriction and ligation, electroporated into DH10β, and the plasmid was purified (Qiagen Plasmid Maxi Kit) and stored in the form of angiotropic plasmid pool (pSub2 is a plasmid prepared by David Schaffer La, UC Berkeley based on pSub201 (ATCC), and is prepared so that the cap gene can be subcloned using HindIII and NotI, Reference 1. Narendra Maheshri et al., Nature Biotechnology, 2006; 2. James T Koerber, Nature Protocols, 2006). Among the various mutants selected through a total of three rounds of in vivo selection, the #2-3 mutant was finally selected as an AAV gene carrier for the prevention and treatment of pulmonary arterial hypertension, and it was confirmed that it possessed the AAV1-based point mutations S430C and I647V (Figure 1).

[0066] 2) Construction of recombinant AAV1 vectors (AAV1#2-3 mutants) (1) Construction of packaging plasmid mutants In the angiotropic plasmid pool, multiple angiotropic cap genes were subcloned into pXX2 (UC Berkeley, David Schaffer Lab) containing HindIII and NotI restriction enzymes for the insertion of cap genes, and multiple angiospecific plasmid mutants were created to carry reporter genes.

[0067] (2) Plasmid transfection into AAV293 cells Generation of AAV1#2-3 mutant Mutant plasmid 17μg, ITR flanked reporter gene (pCMV-GFP or pCMV-LacZ or pCMV-FGF12-IRES-GFP) 17μg, and pHelper 17μg were transfected into AAV293 cells to form a calcium-phosphate complex. After about 48 hours, only the cell pellets were collected and the AAV in the cells was extracted by freezing-thawing. Cell debris was then removed by centrifugation, and benzonase 10U / mL was incubated at 37℃ for 30 minutes to remove nucleic acids released from virus-producing cells.

[0068] The cleavage map of the constructed #2-3 mutant is shown in FIG. 2, and the entire base sequence is the same as that in FIG.

[0069] Generation of wild-type AAV1 17μg of packaging plasmid containing AAV2 rep gene and AAV1 cap gene, 17μg of ITR flanked reporter gene (pCMV-GFP or pCMV-LacZ or pCMV-FGF12-IRES-GFP), and 17μg of pHelper were transfected into AAV293 cells to form a calcium-phosphate complex, and after about 48 hours, only the cell pellets were collected and intracellular AAV was extracted through freezing-thawing. Then, cell debris was removed by centrifugation, and nucleic acids released from virus-producing cells were removed by incubation with benzonase 10U / mL at 37℃ for 30 minutes.

[0070] 3) Purification of AAV1#2-3 mutant The AAV solution was ultracentrifuged using an iodixanol gradient. Iodixanol solutions were prepared at 15%, 25%, 40%, and 54%, and loaded into ultracentrifuge tubes in that order, and the AAV solution was loaded on top of them. After tube sealing, ultracentrifugation was performed using an Optima XE-90 Ultracentrifuge (BECKMAN COULTER) and a Vti65.2 rotor (42,000 RPM, 18°C, 2 hours). The AAV layer located between 54% and 40% iodixanol was extracted, and buffer exchange was performed with PBS buffer containing 0.01% Tween 20 using an Amicon® Ultra-15 Centrifugal Filter (MWCO 100,000).

[0071] 4) Measurement of AAV1#2-3 mutant titer The titers of wild-type AAV1 (wtAAV1) and AAV1#2-3 mutant carrying CMV-FGF12-IRES-GFP were quantified by extracting the viral genome from Dnase I (5U)-resistant viruses by proteinase K treatment, followed by quantitative PCR (qPCR) PCR using CMV-specific primers (5'-ATGGTGATGCGGTTTTGGCAG-3': sequence number 11 and 5'-GGCGGAGTTGTTACGACATTTTGG-3': sequence number 12) together with the respective standards.

[0072] The packaging efficiency of wild-type AAV1 and the recombinant AAV1 vector (#2-3 mutant) was compared by genomic titer and is shown in Figure 5. This indicates that the #2-3 mutant has improved packaging efficiency compared to wild-type AAV1, and that it may be possible to maintain evolutionarily superior individuals.

[0073] Example 2: Confirmation of infection of recombinant AAV1 mutants

[0074] 1) In vitro experiments Wild-type AAV1 and the #2-3 mutant carrying CMV-GFP as a reporter gene for gene transfer efficiency and location analysis were packaged and transfected into human pulmonary arterial smooth muscle cells (HPASMCs; 2 × 10 4 The mice were infected with 100 μl of IgG4 (cells / 20 μL).

[0075] Each virus carried CMV-FGF12-IRES-GFP. When the virus carried GFP, the percentage of GFP-expressing cells among all cultured cells was analyzed by flow cytometry 48 hours after infection of HPASMC (MOI 10,000) to confirm infectivity. The results are shown in Figure 6.

[0076] Figure 6 shows the improvement of transduction efficiency of human pulmonary artery smooth muscle cells (HPASMCs) analyzed by the percentage of cells expressing GFP among all cultured cells, and shows that the #2-3 mutant has superior gene transfer efficiency to vascular cells and tropism to human primary cells (human pulmonary artery smooth muscle cells) compared to wild-type AAV1.

[0077] 2) In vivo experiments The AAV1 wild type and the #2-3 mutant carrying CMV-LacZ were packaged and injected into the trachea of ​​8-week-old C57BL / 6 male mice in the form of an aerosol (5 × 10 11 vg / 100μl).

[0078] To confirm the specificity of the recombinant AAV1 vector (#2-3 variant) in lung tissue, the lungs excised one week after injection into 8-week-old C57BL / 6 male mice were stained with whole mount β-galactosidase to confirm LacZ expression (Figure 3). This confirmed that the vector was efficiently delivered locally to the lung tissue.

[0079] In addition, to confirm the vascular specificity of the recombinant AAV1 vector (#2-3 variant) in lung tissue, the lungs were excised one week after injection from 8-week-old C57BL / 6 male mice, and the presence or absence of LacZ expression in the pulmonary blood vessels was confirmed by X-gal staining, and the results are shown in Figure 7. This confirmed that the vector was efficiently delivered to the pulmonary blood vessels.

[0080] Example 3: Confirmation of pulmonary vascular smooth muscle cell targeting efficiency of recombinant AAV1 mutants

[0081] To evaluate the efficiency of targeting vascular smooth muscle cells in lung tissue, we attempted to quantify the amount of viral genome transferred to multiple cells at the single cell level. The #2-3 mutant carrying LacZ and wtAAV1 were packaged and administered intratracheal injection (5 × 10 11 On the 3rd or 7th day after injection, the lungs were excised and subjected to single cell dissociation, followed by incubation overnight at 4°C with antibodies conjugated to α-SMA (α-SMA-Alexa488, Abcam, ab184675) for cell sorting.

[0082] The ratio of the viral genome transferred to each cell was calculated based on the initial injection dose, normalized with the wtAAV1 value, and the fold change of the #2-3 mutant compared to wtAAV1 was confirmed (*p-value<0.01).

[0083] As shown in Figure 8, the viral genome ratio in samples sorted by using an antibody conjugated to α-sma tended to increase 3.7 ± 0.9-fold and 2.7 ± 0.5-fold in the #2-3 mutant compared to wtAAV1 on Day 3 and Day 7, respectively.

[0084] Example 4: Confirmation of Motility of Recombinant AAV1 Mutants

[0085] After intratracheal injection of the #2-3 mutant and wtAAV1 in aerosol form, they pass through various barriers such as the airway wall, extracellular matrix, and vascular wall to reach vascular smooth muscle cells. As one of the reasons for this, we confirmed Brownian motion in the liquid phase (PBS phase) to prove that not only the tropism of #2-3 but also the mobility of AAV1 is superior.

[0086] 1)1xPBS, static state When wtAAV1 or the #2-3 mutant was dispersed at a concentration of 1.0E+09 vg / ml in 1x PBS (pH 7.4) and the trajectories were observed in the static state, it was confirmed that #2-3 exhibited a diffusion-like movement compared to wtAAV1.

[0087] MSD (Mean squared displacement) is defined as msd(τ) = <Δr(τ)2> = <[r(t + τ) - r(t)] 2 >The equation (r(t) is the vector position at time t, τ is the lag time between two positions (the difference in the trajectories obtained for each vector)) is used to measure Log 10 (MSD 1s ) / pixel 2 The results of the comparison of the AAV1 and #2-3 mutants showed a statistically significant increase (3.12±0.17) compared to AAV1 (2.21±0.49) (*p-value<0.01). In other words, the distance traveled by the #2-3 mutant was increased compared to that of the wtAAV1 mutant in 1×PBS, pH 7.4 (Figure 9).

[0088] Brownian motion refers to the irregular movement of particles in a liquid or gas, while diffusion refers to the relatively directional movement of particles. Diffusion can be considered as a macroscopic expression of Brownian motion, and the diffusion form can be predicted by calculating the average movement of Brownian motion.

[0089] That is, in contrast to AAV1, which shows a track that moves irregularly and remains in a fixed position, the track of the #2-3 mutant showed relatively linear movement and showed a diffusion morphology.

[0090] Example 5: Confirmation of pulmonary vascular tropism of recombinant AAV1 mutants

[0091] 1) Confirmation of the distribution of recombinant AAV1 mutants in lung tissue wtAAV1 or the #2-3 mutant was tagged with Alexa594 and administered intratracheal injection (3 × 10 11 48 hours after injection, the lungs were excised under anesthesia and perfusion through the heart. After fixation with 4% PFA, the lungs were sectioned and colocalization of AAV distribution in the arteriole was confirmed using α-sma antibody (Alexa488).

[0092] Observation of AAV distribution 24 h after intratracheal injection revealed that in the #2-3 mutant, AAV vectors tagged with Alexa594 (a fluorescent substance conjugated to the AAV capsid) migrated from the bronchioles to the arterioles.

[0093] At 48 h after intratracheal injection, most of the #2-3 vectors migrated from the bronchiole to the arterioles, and the AAV vectors were confirmed to be localized in the vascular wall. This was confirmed by colocalization with α-sma antibody, a marker for intravascular smooth muscle cells, confirming the blood vessel tropism of the #2-3 vector. In contrast, at 48 h, wtAAV1 was confirmed to have a large amount of AAV vectors in the air sacs around the blood vessels, but did not show colocalization with α-sma antibody (Figure 10).

[0094] In other words, when the virus was exposed to fluorescence to observe its movement within lung tissue, it was found that wtAAV1 remained around the bronchi or was unable to reach the blood vessels, whereas the #2-3 mutant passed through the bronchi and moved rapidly toward the blood vessels very smoothly, and the genes of the #2-3 vector were found to be concentrated in vascular cells.

[0095] 2) Confirmation of pulmonary vascular tropism by LacZ expression LacZ-carrying wtAAV1 or the #2-3 mutant was administered intratracheally to 8-week-old C57BL / 6 male mice (3 × 10 11 Two weeks later, the mice were anesthetized and perfused by cardiac catheter, then sectioned and stained with X-gal. In contrast to wtAAV1, the #2-3 mutant mice showed LacZ expression in the blood vessels.

[0096] As shown in Figure 11, the #2-3 vector has improved mobility compared to wtAAV1, and improves the rate at which it physically reaches the vascular portion of the lung tissue by passing through the airways and extracellular matrix, and also shows vascular tropism of gathering in the blood vessels. Therefore, the #2-3 vector, which is a recombinant AAV1 of the present invention, is expected to be used as an AAV vector for treating and preventing pulmonary vascular target diseases.

Claims

1. A mutant of an adeno-associated virus serotype 1 (AAV1) capsid protein, wherein the serine at position 430 is replaced with a cysteine ​​and the isoleucine at position 647 is replaced with a valine compared to the amino acid sequence of a wild-type AAV1 capsid protein.

2. A mutant of the AAV1 capsid protein of claim 1 having the amino acid sequence represented by SEQ ID NO:

3.

3. A nucleic acid encoding a mutant of the AAV1 capsid protein of claim 1.

4. The nucleic acid according to claim 3, having the base sequence represented by SEQ ID NO:

4.

5. A recombinant AAV1 vector comprising a nucleic acid encoding a mutant of the AAV1 capsid protein of claim 3.

6. The recombinant AAV vector of claim 5, wherein the AAV1 vector has an improved transduction profile for target tissues compared to an AAV1 wild-type viral vector.

7. The recombinant AAV1 vector of claim 6, wherein the target tissue is a pulmonary vasculature.

8. The recombinant AAV1 vector of claim 7, wherein the pulmonary blood vessel is a pulmonary artery.

9. The recombinant AAV1 vector of claim 5, represented by SEQ ID NO:

7.

10. A pharmaceutical composition comprising the recombinant AAV1 vector of claim 5.

11. The pharmaceutical composition of claim 10, wherein the composition further comprises a pharma- ceutically acceptable carrier.

12. The pharmaceutical composition according to claim 10 for the prevention or treatment of pulmonary arterial hypertension.

13. 11. The pharmaceutical composition of claim 10, wherein the composition is administered by intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcuticular, intravitreal, intraarticular, subthecal, subarachnoid, intraspinal, epidural, and intrasternal injection.

14. A method for preventing or treating pulmonary arterial hypertension, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising the recombinant AAV1 vector of claim 5.

15. 15. The method for preventing or treating pulmonary arterial hypertension according to claim 14, wherein the composition is administered by intravenous, intraperitoneal, intramuscular, intra-arterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcuticular, intravitreal, intra-articular, subthecal, subarachnoid, intraspinal, epidural, or intrasternal injection.

Citation Information

Patent Citations

  • High-transduction-efficiency rAAV vector, composition, and method of use

    JP2015519895A

  • Molded solder and method for manufacturing molded solder

    KR1020200036745A

  • AAV vectors for gene delivery to the lung

    US20080292595A1

  • JP2021-0010372B

  • Recombinant AAV for gene therapy in lungs

    WO2017201121A1